Welcome to our dedicated page for Hillstream BioPharma news (Ticker: hils), a resource for investors and traders seeking the latest updates and insights on Hillstream BioPharma stock.
Hillstream BioPharma, Inc. (NASDAQ: HILS) is a cutting-edge biotechnology company dedicated to developing innovative therapeutic candidates targeting drug-resistant and devastating cancers. The company's proprietary Quatramer™ technology enables targeted delivery and extended action of biologics, mRNA, peptides, and other therapeutic modalities within the tumor microenvironment, minimizing off-target toxicity.
Hillstream's notable advancements include Quatrabody™ conjugates, which exhibit higher binding affinity to immuno-oncology targets than currently approved therapies. Emerging as a leader in immuno-oncology, Hillstream is set to enter the market with its leading candidate HSB-1940, targeting PD-1, followed by other targets such as PD-L1, HER-2, and TROP-2.
Recent achievements highlight Hillstream's exclusive license agreement with the Applied Biomedical Science Institute (ABSI), which allows the company to develop novel antibodies targeting HER2 and HER3. These antibodies are distinct from existing therapies and present a promising approach to treating HER2-positive cancers.
Hillstream's focus on oncology includes developing HSB-3215, a bi-specific antibody targeting HER2 and HER3. Through collaborations with Minotaur Therapeutics and OmniAb, Inc., Hillstream is advancing the development of next-generation biotherapeutics, including Picobodies™ against HER3 and other undisclosed oncology targets.
In addition to oncology, Hillstream is expanding its therapeutic pipeline with the acquisition of AV104, a clinical-stage asset for treating chronic pruritis, including conditions such as primary biliary cholangitis (PBC). This asset utilizes a proprietary transdermal buccal film for effective delivery and high drug concentrations in the skin.
Hillstream BioPharma's strategic focus on advancing its robust immuno-oncology pipeline and acquiring clinical-stage assets positions the company as a significant player in the biotechnology sector. For further information, please visit www.hillstreambio.com.
Hillstream BioPharma, Inc. (Nasdaq: HILS) has partnered with OncoBay Clinical to support the clinical development of HSB-1216, its lead drug candidate targeting drug-resistant cancers via ferroptosis. The collaboration aims to utilize OncoBay’s expertise in clinical and regulatory support, which includes data management and statistical programming. Hillstream anticipates submitting an investigational new drug application and commencing clinical studies in the second half of 2023. The partnership is expected to accelerate the development of HSB-1216, which aims to leverage iron-mediated cell death to combat challenging cancers. Hillstream's pipeline also includes HSB-3215, a novel anti-HER2 monoclonal antibody. Hillstream believes that the extensive oncological expertise of OncoBay and its ties to Moffitt Cancer Center position the partnership for success.
Hillstream Biopharma is capitalizing on the rapid growth of the global oncology market, which was valued at $286.04 billion in 2021 and is projected to exceed $581.25 billion by 2030, growing at a CAGR of 8.2% from 2022 to 2030. The company is advancing its lead drug candidate, HSB-1216, designed to target solid tumors through ferroptosis, which is the first of its kind. Utilizing the proprietary Quatramer platform, HSB-1216 aims to minimize off-target toxicity while effectively treating cancers like triple-negative breast cancer. Early preclinical results have been promising, indicating its potential to transform cancer treatment. CEO Randy Milby, an experienced industry leader, is spearheading this innovation, marking a significant step forward in the quest for effective cancer therapies.
Hillstream BioPharma (Nasdaq: HILS) announced positive pharmacokinetic (PK) data for its drug candidate HSB-1216, highlighting its potential in targeting drug-resistant cancers. The recent IND-enabling studies demonstrated that the Quatramer™ technology effectively protected HSB-1216 from metabolic degradation, ensuring its release directly at tumor sites, consistent with previous pre-clinical results indicating tumor growth reduction.
The studies showed promising preliminary safety and PK profiles in both rats and dogs, supporting Hillstream's ongoing development strategy. The company plans to submit an investigational new drug application for HSB-1216 in the second half of 2023, aiming to target ferroptosis, a novel anti-cancer mechanism.
Hillstream BioPharma (Nasdaq: HILS) announced participation in two significant industry conferences in April 2023. The BioNJ BioPartnering Conference will be held on April 17-18 in Somerset, NJ, and the CPHI North America Conference on April 25-27 in Philadelphia, PA. CEO Randy Milby will present and conduct one-on-one meetings with analysts and investors at both events, discussing operational highlights and pipeline candidates, including HSB-1216 and HSB-3215. Both conferences aim to foster collaboration and innovation in the pharmaceutical sector.
Hillstream BioPharma, Inc. (Nasdaq: HILS) has announced its participation in the 35th Annual Roth Conference from March 12-14, 2023, at The Ritz-Carlton Hotel, California. The company will hold one-on-one meetings with institutional investors and analysts, showcasing its investment thesis and therapeutic candidates targeting drug-resistant cancers through innovative mechanisms like ferroptosis. Recently, Hillstream signed an exclusive option agreement with Applied Biomedical Science Institute to license technology for HER2 and HER3. The CEO expressed eagerness for the conference, highlighting its significance for networking and investment opportunities.
Hillstream BioPharma (Nasdaq: HILS) has regained compliance with Nasdaq's minimum bid price requirement, achieving a closing bid price of over $1.00 for ten consecutive trading days as of February 13, 2023. The company held a virtual R&D Day on February 14, discussing its four pipeline candidates and recent agreements, including an exclusive option with Applied Biomedical Science Institute for HER2 and HER3 technologies targeting drug-resistant cancers. Additionally, a preclinical study of HSB-1216, in combination with pembrolizumab, showed positive results against KRAS-G12C-mutated non-small cell lung cancer cells. The oncology market is projected to reach $11 billion by 2028.
Hillstream BioPharma has signed an exclusive option agreement with the Applied Biomedical Science Institute to license technology aimed at drug-resistant cancers, including HER2-positive metastatic breast cancer and others. The company is focused on developing therapeutic candidates that utilize ferroptosis, a novel anti-cancer mechanism. Recent preclinical studies of HSB-1216 showed significant tumor inhibition when combined with pembrolizumab against KRAS G12C-mutated non-small cell lung cancer cells. Hillstream aims to address key oncology markets projected to reach $11 billion by 2028 and will host a virtual R&D Day on February 14, 2023.
FAQ
What is the market cap of Hillstream BioPharma (hils)?
What does Hillstream BioPharma specialize in?
What is the Quatramer™ technology?
What recent collaborations has Hillstream BioPharma announced?
What is HSB-3215?
What is AV104?
How does Hillstream plan to address unmet needs in oncology?
What other therapeutic areas is Hillstream exploring?
What is the significance of Hillstream's collaboration with ABSI?
What makes Picobodies™ unique?
Where can I find more information about Hillstream BioPharma?
